As Covid-19 drug and vaccine developers race to figure out which of their products might be hampered by the new variant, the CDC on Wednesday afternoon announced the first confirmed case of the…
Paul Hudson has spotlighted vaccines, immunology and dermatology as some of the top R&D focuses at Sanofi. His latest deal brings all of them together. The French pharma giant isn’t sharing any…
J&J and Sanofi have gone back and forth in their multiple myeloma tug-of-war. Earlier this year, Sanofi notched an approval of Sarclisa in combination with Amgen’s Kyprolis to try to outflank the big…
Wednesday brought another win for South Dakota’s biggest transgenic cow so far. SAB Biotherapeutics, which develops treatments by collecting and distilling antibodies from cows with humanized immune…
The US Court of Appeals for the Federal Circuit on Wednesday rejected Moderna’s attempt to overturn key patents related to the delivery vehicle for its Covid-19 vaccine after the biotech sought to…
Vertex claimed its second early-stage win of the fall Wednesday, announcing positive results in a small study on a genetically defined form of kidney disease. The 16-patient, Phase II trial focused on…
Amid a renaissance in the field of radiopharmaceuticals, a growing chorus of biopharma players is rushing the stage to capitalize on tech breakthroughs. Biotech blue-chippers RA Capital and Atlas…
GlaxoSmithKline is inviting everyone to its friendly shark tank. Its ‘Think Tank’ challenge launching today aims to gather the best pitches for ideas in multiple myeloma with a final pitch-off ‘Shark…
BeyondSpring shocked investors in early August after its once-marginal lead drug suddenly showed a lot of promise in a common form of lung cancer. With hopes high, the FDA has now slammed the door on…
In a first, China has featured insulin in its centralized drug procurement program — but the bulk order comes at a sizable cost for multinational pharma players. Novo Nordisk, Sanofi and Eli Lilly…
